The use of amiodarone with HCV treatments and another direct acting antiviral can result in symptomatic bradycardia, or serious slowing of the heart.
The FDA is recommending healthcare professionals not prescribe Harvoni or Sovaldi combined with another direct acting antiviral, such as daclatasvir or Olysiom, and amiodarone.
More articles on gastroenterology:
PENTAX Medical names new America’s president & chief marketing officer
7 statistics on Match Day for GI
7 things for gastroenterologists to know for today – March 20, 2015
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
